Introduction {#S1}
============

Tau, a microtubule-associated protein mainly expressed in neurons, is involved in polymerizing microtubules and maintaining microtubule stability under physiological conditions ([@B21]; [@B31]; [@B58]). The majority of soluble tau is bound to microtubules, stabilizing them by shifting the equilibrium from free tubulin and microtubules toward polymerization. The physiological functions of tau are highly regulated by a wide range of posttranslational modifications, including phosphorylation, acetylation, glycation, isomerization, nitration, SUMOylation, and ubiquitination ([@B36]). The alteration of these modifications can affect tau functions and potentially lead to pathological conditions. Hyperphosphorylation of tau causes its detachment from microtubules, thereby impairing the axonal stability and trafficking necessary for normal neuronal activities ([@B36]).

Research indicates that the interaction of tau with microtubules is not as stable as previously believed ([@B29]), and tau exerts diverse functions that interact with multiple binding partners ([@B36]). Using single-molecule tracking experiments, [@B29] showed that tau interacts with microtubules in a highly dynamic manner, with dwell time in the milliseconds range. The dynamic behavior of tau may underlie the regulation of microtubule dynamics and other functions coordinated with multiple binding partners. Tau interacts with plasma membrane-binding protein annexins, which may contribute to the enrichment and distribution of tau intracellularly and contribute to tau's release from the cells ([@B17]). The rapid, dynamic behavior of tau may be essential for its non-microtubule-related functions and its interactions with multiple binding partners in the cell ([@B36]).

Tau is also known as a major component of neurofibrillary tangles (NFTs), one of the cardinal pathological features in Alzheimer's disease (AD) ([@B25]; [@B50]). A cross-sectional neuropathological study showed that the tau pathology of AD typically spreads from one area to another in a stereotypical pattern along a neural network ([@B4]). In early stage AD, NFTs appear in the transentorhinal cortex in the medial temporal lobe and later spread across the entire cerebral cortex via the hippocampal areas (Braak staging of NFT) ([@B4]). The mechanism underlying the stereotypical progression pattern of NFT in AD has not been elucidated; however, findings from recent studies suggest that tau pathology potentially spreads by the interneuronal transfer of the pathological from of tau ([Figure 1](#F1){ref-type="fig"}; [@B26]; [@B37]; [@B18]). This phenomenon, called "tau propagation," gains attention as a pathological hypothesis explaining the reason why AD progresses over time and also as a new therapeutic target for AD.

![Propagation of tau pathology in Alzheimer's disease (AD) brain. The tau pathology in the AD brain \[neurofibrillary tangles (NFTs)\] is known to spread along a neural network in a stereotypical manner. Interneuron transfer of the pathological form of tau may underlie the stereotypical progression of AD neuropathology (tau propagation hypothesis).](fnins-13-01274-g001){#F1}

Tau Pathology in the Brain of Patients With Dementia {#S2}
====================================================

Tauopathy and Isoforms of Tau {#S2.SS1}
-----------------------------

A class of neurodegenerative disorders characterized by intracellular aggregates of tau in the brain, including AD, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, and argyrophilic grain disease, are collectively called tauopathy. Six isoforms of tau are known to be present in the human adult brain, and, in terms of the number of microtubule-binding repeats, tau isoforms are divided into two groups: 3-repeat and 4-repeat tau. A distinct pattern of tau accumulation is observed in each tauopathy: tau aggregates are present in either or both forms of tau isoforms -- for example, 3-repeat tau in Pick's disease; 4-repeat tau in corticobasal degeneration, progressive supranuclear palsy, and argyrophilic grain disease; and both 3-repeat and 4-repeat tau in AD ([@B31]). The differences in biochemical characteristics, including isoforms, of accumulated tau, are closely related to the pattern of progression of the tau pathology in each tauopathy (initial region and/or patterns of subsequent progression), which is important in understanding the tau propagation hypothesis.

Progression Pattern of Tau Pathology in the Brain of AD Patients {#S2.SS2}
----------------------------------------------------------------

Neurofibrillary tangles in AD patients appear first in the transentorhinal cortex or the entorhinal cortex in the medial temporal lobe (Braak stages I and II), then gradually progress to the hippocampal region (Braak stages III and IV), and finally involve the association neocortex or the primary areas of the neocortex (Braak stages V and VI) ([@B50]). This pattern of NFT progression closely resembles the clinical course of AD, which starts with severe memory deficit and slowly progresses to another cognitive dysfunction, indicating that the spread of the tau pathology is deeply associated with neurological dysfunction ([@B45]; [@B13]). Since the progression of the tau pathology appears to spread along neuroanatomical connections, in other words, a brain region to another via axonal projections, the tau propagation hypothesis has been proposed, in which the pathological form of tau transfers between neurons ([@B8]; [@B56]).

Tau Propagation {#S3}
===============

Tau Propagation *in vitro* {#S3.SS1}
--------------------------

*In vitro* experiments performed by [@B16] showed that a tau seed added to a culture medium can be taken up into cells via endocytosis and form new intracellular aggregates of tau. This finding provided theoretical evidence for the interneuronal transfer of tau as a mechanism underlying tau propagation.

Following the paper by [@B16] multiple research groups reported on the mechanisms of the cellular uptake of extracellular tau and subsequent intracellular aggregation. A better understanding of the biochemical features of the tau involved in propagation is important in developing therapeutic strategies ([@B47]; [@B41]). The first report by [@B16] showed that the fibrillar form of tau is more easily taken up into the cells than the monomeric form of tau. On the other hand, [@B35] reported that the tau trimer is the minimal unit that is capable of inducing intracellular aggregates of tau. [@B60] and [@B55] performed experiments using a unique chamber for neuronal cell culture with a microfluidic chip demonstrating that the tau oligomer is more easily propagated than the tau monomer. Another report demonstrated that the monomeric form of tau can mediate tau propagation ([@B34]). To date, which form of tau is really involved in interneuronal propagation remains controversial ([Table 1](#T1){ref-type="table"}).

###### 

The nature of tau species involved in propagation.

  **The nature of tau species**                                                                   **Origin of tau seeds**                                                     **Experimental model**                                                                                                                        **References**
  ----------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  Tau monomer                                                                                     Recombinant tau                                                             Tau uptake in cell culture model                                                                                                              [@B34]
  Tau trimers                                                                                     Recombinant tauBrain-derived tau from AD brain                              Tau uptake in cell culture model                                                                                                              [@B35]
  Tau oligomers (dimer/trimer)                                                                    Brain-derived tau from AD brain                                             Intracereberal injections of tau seeds in mouse model                                                                                         [@B30]
  Low-molecular-weight aggregates (spherical oligomers with diameters ranging from 10 to 30 nm)   Recombinant tau                                                             Trans-synaptic transfer of tau in microfluidic devices                                                                                        [@B60]
  Phosphorylated large tau oligomers (\>10 mers)                                                  Brain-derived tau from tau-transgenic mice                                  Tau uptake in cell culture modelIntracereberal injections of tau seeds in mouse model                                                         [@B28]
  Phosphorylated high-molecular-weight tau (\>600 kDa)                                            Brain-derived tau from AD brainBrain-derived tau from tau-transgenic mice   Tau uptake in cell culture modelTrans-synaptic transfer of tau in microfluidic devicesIntracereberal injections of tau seeds in mouse model   [@B55]
  Tau aggregates                                                                                  Recombinant tau                                                             Tau uptake in cell culture model                                                                                                              [@B16]
  Tau aggregates                                                                                  Exosomal tau from primary neurons or cerebrospinal fluid of AD patients     Tau uptake in cell culture modelTrans-synaptic transfer of tau in microfluidic devices                                                        [@B57]
  Tau fibrils                                                                                     Recombinant tau                                                             Intracereberal injections of tau seeds in mouse model                                                                                         [@B27]
  Tau fibrils                                                                                     Brain-derived tau from AD brain                                             Intracereberal injections of tau seeds in mouse model                                                                                         [@B22]

AD, Alzheimer's disease.

The aggregation and propagation properties of tau also depend on its isoforms ([@B40]; [@B14]). Variations of the tau isoform can affect posttranslational modification, such as the fragmentation and phosphorylation of tau, which can potentially modify intracellular uptake and aggregation capability ([@B12]). The propagation activity of tau can also be affected by the type of genetic mutation or the origin of tau (synthetic or brain-derived tau protein) ([@B31]).

Tau Propagation in Animal Models {#S3.SS2}
--------------------------------

[@B7] reported that intracellular tau aggregates can be induced in the mouse brain that was injected with seed-competent tau aggregates, demonstrating that tau propagation may occur even *in vivo*. In this experiment, brain homogenates from tau-transgenic mice that overexpress the mutant form of tau in the brain were injected into another mouse brain that does not have the tau pathology; 12 months later, tau aggregates were observed in the neurons of the recipient mouse brain.

In 2012, three research groups independently reported almost similar mouse models of tau propagation ([@B10]; [@B23]; [@B32]). Transgenic mice overexpressing human mutant tau (P301L) only in the entorhinal cortex were generated using a region-specific promoter, and the neuropathological changes were examined over time up to 2 years. First, the tau pathology appeared in the entorhinal cortex (where the human mutant tau was overexpressed) at the age of 12 months and then appeared in the neurons of the dentate gyrus, which has strong neuroanatomical connection to the entorhinal cortex but is not supposed to express the human mutant tau, at the age of about 18 months. These experiments demonstrated that, although there are some problems/limitations including the region specificity of the promoter, tau pathologies that comprise the human mutant tau in neurons of the entorhinal cortex can potentially spread likely via synaptic transmission to neurons in the dentate gyrus, a major target of axonal projections.

Along the same line, [@B27] and [@B1] conducted *in vivo* experiments wherein the fibrillar form of recombinant tau, or tau-transgenic mouse brain-derived tau, was injected into a specific region of the mouse brain that does harbor the tau pathology. Newly induced tau pathology appeared in the brain regions along a neural network from the injection site. The region where the tau pathology appeared was not related to the distance from the tau seed injection site but to a neuroanatomical connection (along the axonal projection), implying that tau propagation possibly occurs via synapses.

Mechanism of Tau Propagation {#S3.SS3}
----------------------------

Although researchers have demonstrated that certain forms of pathological tau have the property of transmission between neurons ([@B6]), the molecular mechanisms underlying tau propagation are still largely unknown. The interneuronal propagation of tau is divided into three steps: the intracellular pathological tau (1) is released into the extracellular space, (2) is taken up by recipient cells, and (3) forms new intracellular aggregates in the recipient cells ([Figure 2](#F2){ref-type="fig"}).

![Neuron-to-neuron transfer of tau. The processes involved in tau propagation can be divided into three basic steps: (1) the pathological form of tau is released into the extracellular space from the donor cell; (2) the pathological tau released into the extracellular space is taken up by recipient cells; and (3) the pathological tau taken up into the recipient cells forms new intracellular aggregates. Tau exists in various forms in terms of biochemical property, including monomeric, oligomeric, truncated, and phosphorylated forms. Additionally, tau may undergo a wide range of posttranslational modifications, including acetylation, glycation, isomerization, nitration, SUMOylation, and ubiquitination or a mixture of these modifications. It is still largely unknown which forms of tau are released into the extracellular space and involved in tau propagation.](fnins-13-01274-g002){#F2}

Regarding tau release into the extracellular space, passive leakage from degenerated cells and tau dissociation from ghost tangles likely contribute to it. Recent studies have shown a possibility that physiological active tau release could occur without neurodegeneration ([@B62], [@B63]; [@B44]), which may be involved in tau propagation ([@B61]). The cellular uptake of extracellular tau can potentially be mediated by endocytosis ([@B24]) occurring on the cell surface or during synaptic transmission. A recent study by [@B15] showed that seed-competent tau enters cells via clathrin-independent endocytosis and escape from damaged endomembranes into the cytosol, triggering cytosolic tau aggregation. The galectin-8-dependent autophagy system mediated the delivery of tau seeds from the endo-lysosomal pathway to the cytosol, implying a role for autophagy in intracellular tau aggregation and propagation.

Tau propagation is known to occur in both directions (retrograde and anterograde) along a neural network ([@B1]; [@B55]), which indicates that tau propagation does not necessarily occur only via synaptic transmission. Asai et al. and other researchers reported that exosomes are also involved in the mechanism that mediates interneuronal tau transfer ([@B2]; [@B57]).

Propagation of Other Pathological Proteins {#S3.SS4}
------------------------------------------

Researchers have reported on other proteins implicated in neurodegenerative diseases, including amyloid-β ([@B43]; [@B59]; [@B49]; [@B9]; [@B46]) or α-synuclein ([@B11]; [@B33]; [@B52]), which show the key biochemical properties and capabilities of cell-to-cell propagation. Although they show distinct distributions in the human brain, misfolded forms of these pathological proteins may propagate through mechanisms similar to tau ([@B19]). In the brains of AD patients, amyloid-β plaques develop in the basal temporal and orbitofrontal cortex in the early phase before reaching other areas, such as the neocortex, hippocampal formation, and basal ganglia, and then finally spreading to the lower brain stem. Inclusions of α-synuclein first develop in the peripheral nervous system and olfactory bulb, ascend to the brainstem and midbrain, and then spread to the basal forebrain and neocortex ([@B5]; [@B19]). Distinct conformations of each pathological protein may determine the distribution pattern and speed of spread and may underlie the phenotypic diversity of neurodegenerative diseases. Although the molecular mechanisms mediating the propagation of pathological proteins have not been fully understood, they can be specific targets for therapeutic interventions.

Unsolved Questions Regarding Tau Propagation Hypothesis {#S4}
=======================================================

Tau propagation is an intriguing pathological hypothesis for explaining the fundamental characteristics of dementia that progresses over time, but many questions regarding its mechanisms or the validity of the hypothesis still remain unsolved.

It is necessary to carefully examine how exactly the tau pathology in cultured cells and brains of animal models reflects the tau pathology observed in the human brain. So far, there is no clear evidence showing biochemical and biological similarities between the structures of tau aggregates in cultured cells or mouse brains and those of the NFTs in AD patients.

In humans, the accumulation of tau aggregates is accompanied by various cognitive dysfunctions associated with neuronal death; however, with some exceptions, the tau pathology induced in cell lines or mouse brains is often not accompanied by neuronal death or dysfunction. This may be because the tau seeds used in experimental models for propagation study are not identical to the species that exert neurotoxicity in human tauopathies. Moreover, scientists do not know which species of tau is really involved in neurotoxicity ([@B3]). Propagation property and neurotoxicity may be independent features of distinct forms of tau. Additionally, most experiments based on cell or animal models with overexpression of the mutant form of tau may not accurately reflect the brain pathology in patients with sporadic AD without genetic mutation.

There are some issues regarding the validity of the concept of tau propagation. In the tau propagation hypothesis, the medial temporal lobe is considered an initial site of origin for tau propagation starting in the brain of AD patients. However, the tau pathology in AD is known to begin in areas such as the dorsal raphe nuclei ([@B20]) and the locus coeruleus ([@B48]) or it can also begin in the area of the neocortex rather than the medial temporal lobe ([@B4]; [@B31]). The dorsal raphe nuclei and locus coeruleus are connected with the transentorhinal cortex where tau pathology develops in the early stages of AD. These nuclei may be affected by tau pathology even before the transentorhinal cortex, and they may act as an initiation site for the subsequent spread of tau pathology throughout the brain ([@B20]; [@B48]).

The heterogenicity of the distribution of the AD tau pathology should also be taken into consideration when understanding the propagation hypothesis; the initial site of origin for tau propagation may not be limited to only one site, but multiple brain regions could be the starting points of propagation instead. Tau aggregates also appear in glial cells in some types of tauopathies, but the applicability of the tau propagation hypothesis to glial tau pathology remains unclear.

Some fundamental issues have not been solved, including why conformational changes and aggregation initiate at the initial site of origin for tau propagation. What is the most upstream trigger of tau aggregation in the initial site? In human tauopathy, even in cases caused by genetic mutation in which all cells are supposed to uniformly possess the same mutation, a striking laterality of neuropathology is occasionally observed. Can the tau propagation hypothesis explain the asymmetricity observed in some cases of tauopathy? These unsolved questions need to be discussed and answered for a better understanding of tau propagation.

Future Directions: Toward Diagnosis and Treatment Based on the Tau Propagation Hypothesis {#S5}
=========================================================================================

A stereotypical pattern of the progression of the tau pathology in the brains of patients with sporadic AD may be explained by the tau propagation hypothesis, which can potentially lead to the development of diagnostic and treatment strategies for AD ([@B51]; [@B53]).

[@B54] examined the biological and biochemical properties of brain extracellular tau from various sources including lumbar cerebrospinal fluid (CSF) from AD patients. They found that the bioactive tau species involved in propagation is present in the CSF from AD patients, and its concentrations were significantly higher than those in control subjects or patients with frontotemporal dementia. This finding suggests that the tau species involved in propagation could be useful as a biomarker for AD, specifically for monitoring tau propagation activity.

The tau propagation hypothesis, based on the concept that the clinical progression of AD is linked with the spreading of the tau pathology, supports the idea that clearing the tau involved in propagation may slow the spread of the tau pathology and possibly of cognitive decline ([@B38]; [@B39]). The potential efficacy of antibody-based therapeutics targeting tau has been demonstrated in several studies using animal models ([@B64]; [@B42]), although it is unclear how an antibody can exert its therapeutic efficacy against an intracellular protein such as tau. In this regard, the tau propagation hypothesis may provide a rationale for the antibody-based strategy targeting tau propagation that could be mediated by extracellular tau, which can be captured and neutralized by an anti-tau antibody; the antibody does not need to be incorporated into the cell to exert its therapeutic efficacy ([@B53]).

Identifying the most efficient epitope should be critical in therapeutic development for tau-based immunotherapy. So far, various antibodies against distinct epitopes of tau have been tested ([@B53]). Some antibodies successfully ameliorated the cognitive deficit and neuropathology in mouse models. [@B39] used a cell culture model to assess the effect of multiple anti-tau antibodies on tau propagation to identify suitable target epitopes for blocking tau uptake and propagation. The blocking efficacy varied depending on the epitope that each anti-tau antibody targeted, and the antibody against the N-terminal and phospho-site of tau showed the most effectiveness ([@B39]). Other processes involved in tau propagation, including tau release, cellular uptake, and intracellular aggregation, could be therapeutic targets for halting the spread of the tau pathology, which need further investigation.

Conclusion {#S6}
==========

This article reviewed the recent findings regarding the tau propagation hypothesis, namely, the basic concept and evidence of tau propagation, potential as a diagnostic and therapeutic target, and unsolved questions. The hypothesis has been attracting considerable attention in the research field of ADbecause it may explain the stereotypical progression of the tau pathology in the brain of AD patients and provides a rationale for tau-based therapies. Numerous questions regarding the detailed molecular mechanisms underlying the tau propagation remain unanswered. Identifying the specific tau species involved in propagation, molecules mediating tau release and uptake, and surrogate markers for propagation activity should be the key research targets for tackling tau propagation.

Author Contributions {#S7}
====================

The author confirms being the sole contributor of this work and has approved it for publication.

Conflict of Interest {#conf1}
====================

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by JSPS KAKENHI Grant Number 17H05080 \[Grant-in-Aid for Young Scientists (A)\].

[^1]: Edited by: Yumiko Motoi, Juntendo University, Japan

[^2]: Reviewed by: Tadanori Hamano, University of Fukui, Japan; Roland Brandt, Osnabrück University, Germany

[^3]: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
